Therapeutics: Receptor-interacting serine-threonine kinase 1 (RIPK1; RIP1); RIPK3 (RIP3); mixed-lineage kinase domain-like (MLKL)
By BC Staff | Aug 4, 2016 | 7:00 AM GMT
Cardiovascular disease
INDICATION: Atherosclerosis
Patient sample and mouse studies suggest inhibiting the necroptosis-related proteins RIPK1, RIPK3 or
Read the full 152 word article
